Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-AS02V vs HBVAXPRO in Hepatitis B Non-Responders
NCT00291954Phase 3Completed
- Sponsor
- Henogen
- Start
- Mar 2006
- Primary completion
- Oct 2007
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of adjuvanted hepatitis B vaccine HB-AS02V in hepatitis B (HBV) (2 arms), sponsored by Henogen. Primary endpoint: Anti-HBs seroprotection rate at Month 2. Started Mar 2006; status: completed.
02
Drugs
adjuvanted hepatitis B vaccine HB-AS02V
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00291954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00291954.